Drug Type Bispecific antibody |
Synonyms AMG-994 |
Target |
Action agonists, inhibitors |
Mechanism CD40 agonists(Tumor necrosis factor receptor superfamily member 5 agonists), MSLN inhibitors(Mesothelin inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |


| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | United States | 29 Apr 2021 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | Japan | 29 Apr 2021 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | Australia | 29 Apr 2021 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | Belgium | 29 Apr 2021 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | Canada | 29 Apr 2021 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | France | 29 Apr 2021 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | Germany | 29 Apr 2021 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | Poland | 29 Apr 2021 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | Spain | 29 Apr 2021 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | United Kingdom | 29 Apr 2021 |
Phase 1 | 11 | rgxnibcuix = ttivhmazcr ytlrsogins (ctqwytemde, ocahabjocf - iygxombrua) View more | - | 06 Jan 2025 | |||
rgxnibcuix = bqxrxdoxlv ytlrsogins (ctqwytemde, zvkncgcjyx - cawbphbrvk) |






